# MDFI

## Overview
MDFI, or MyoD family inhibitor, is a gene that encodes a protein involved in the regulation of myogenic differentiation. The protein, also referred to as MDFI, functions as a transcriptional regulator by interacting with the MyoD family of transcription factors, which are crucial for muscle cell differentiation. As a cytoplasmic protein, MDFI inhibits the nuclear localization and DNA binding activity of these transcription factors, thereby modulating their ability to activate gene transcription necessary for myogenesis (Hou2019MiR5013p; Sui2020Opposite). Beyond its role in muscle development, MDFI is implicated in various signaling pathways, including the Wnt/β-catenin pathway, and has been associated with both tumor-suppressing and tumor-promoting activities in different cancer types (Sui2020Opposite; Vafaeie2022ACAN). This dual role underscores the complexity of MDFI's function in cellular processes and disease states.

## Function
MDFI (MyoD family inhibitor) is a protein that plays a crucial role in regulating myogenic differentiation by interacting with the MyoD family of transcription factors. It functions primarily by inhibiting the nuclear localization and DNA binding activity of these transcription factors, thereby repressing their ability to activate gene transcription necessary for muscle cell differentiation (Sui2020Opposite). MDFI is predominantly localized in the cytoplasm, where it retains MyoD family proteins, preventing them from entering the nucleus and initiating myogenesis (Hou2019MiR5013p).

In C2C12 myoblasts, MDFI has been shown to promote differentiation by increasing the expression of myogenic markers such as MyoD, Myogenin, and Myosin, indicating its role in enhancing myogenic differentiation (Huang2021Mdfi). MDFI also influences muscle fiber type transformation, particularly promoting the shift from fast-twitch to slow-twitch muscle fibers, which is associated with increased mitochondrial activity and oxidative metabolism (Huang2021Mdfi).

MDFI's interaction with signaling pathways, such as the Wnt/β-catenin pathway, further modulates its inhibitory effects on myogenesis, suggesting a complex regulatory role in muscle development and regeneration (Sui2020Opposite).

## Clinical Significance
The MDFI gene has been implicated in various cancers due to alterations in its expression levels and interactions. In gastric cancer, MDFI is identified as a hub-gene, acting as a tumor suppressor by inhibiting the Wnt/beta-catenin signaling pathway, which is often dysregulated in cancers (Vafaeie2022ACAN). However, MDFI expression is upregulated in brain, gastric, and pancreatic tumors, suggesting potential tumor-promoting activities (Vafaeie2022ACAN).

In lung adenocarcinoma (LUAD), MDFI is overexpressed and associated with poor prognosis. High MDFI expression correlates with worse clinical outcomes and is considered an independent prognostic factor (Chen2022MDFI). The gene's expression is also linked to immune cell infiltration, potentially playing a role in immune escape within the tumor microenvironment (Chen2022MDFI).

In colorectal cancer, MDFI is significantly methylated, which may contribute to cancer initiation and progression. This methylation serves as a potential biomarker for early-stage colorectal cancer (Li2017DNA). MDFI is overexpressed in colorectal tumors, promoting tumor growth, while its homolog MDFIC acts as a tumor suppressor (Sui2020Opposite). These findings highlight MDFI's complex role in cancer, acting as both a tumor suppressor and promoter depending on the context.

## Interactions
MDFI (MyoD family inhibitor) is known to interact with several proteins, primarily involved in myogenic transcription regulation. It was originally identified as an interaction partner of the MyoD family of myogenic transcription factors, where it represses their ability to activate gene transcription. This repression is achieved through two mechanisms: retention of these myogenic factors in the cytoplasm and inhibition of their nuclear DNA binding activity (Sui2020Opposite). MDFI also interacts with the TCF/LEF-1 transcription factor, a downstream effector in the WNT/β-catenin signaling pathway, and with β-catenin itself. This interaction prevents MDFI from binding to MyoD family members, suggesting a mechanism by which WNT signaling could overcome MDFI's inhibitory effects on myogenesis (Sui2020Opposite).

MDFI forms a complex with the histone demethylase JMJD1A, but not with other homologous JMJD proteins. This interaction involves the cysteine-rich C-termini of MDFI, which is responsible for the binding (Sui2020Opposite). MDFI's interaction with JMJD1A and its altered expression levels may play a role in colorectal cancer development and progression (Sui2020Opposite). These interactions highlight MDFI's role in modulating transcriptional activity and its potential involvement in cancer biology.


## References


[1. (Hou2019MiR5013p) Lianjie Hou, Linhui Zhu, Huaqin Li, Fangyi Jiang, Lingbo Cao, Ching Yuan Hu, and Chong Wang. Mir-501-3p forms a feedback loop with fos, mdfi, and myod to regulate c2c12 myogenesis. Cells, 8(6):573, June 2019. URL: http://dx.doi.org/10.3390/cells8060573, doi:10.3390/cells8060573. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells8060573)

[2. (Sui2020Opposite) Yuan Sui, Xiaomeng Li, Sangphil Oh, Bin Zhang, Willard M. Freeman, Sook Shin, and Ralf Janknecht. Opposite roles of the jmjd1a interaction partners mdfi and mdfic in colorectal cancer. Scientific Reports, May 2020. URL: http://dx.doi.org/10.1038/s41598-020-65536-6, doi:10.1038/s41598-020-65536-6. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-020-65536-6)

[3. (Vafaeie2022ACAN) Farzane Vafaeie, Samira Nomiri, Javad Ranjbaran, and Hossein Safarpour. Acan, mdfi, and chst1 as candidate genes in gastric cancer: a comprehensive insilco analysis. Asian Pacific Journal of Cancer Prevention, 23(2):683–694, February 2022. URL: http://dx.doi.org/10.31557/apjcp.2022.23.2.683, doi:10.31557/apjcp.2022.23.2.683. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.31557/apjcp.2022.23.2.683)

[4. (Chen2022MDFI) Pengyu Chen, Zhen Quan, Xueyu Song, Zhaojia Gao, and Kai Yuan. Mdfi is a novel biomarker for poor prognosis in luad. Frontiers in Oncology, October 2022. URL: http://dx.doi.org/10.3389/fonc.2022.1005962, doi:10.3389/fonc.2022.1005962. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.1005962)

[5. (Li2017DNA) Jinyun Li, Cheng Chen, Xuer Bi, Chongchang Zhou, Tao Huang, Chao Ni, Ping Yang, Si Chen, Meng Ye, and Shiwei Duan. Dna methylation of cmtm3 , sstr2 , and mdfi genes in colorectal cancer. Gene, 630:1–7, September 2017. URL: http://dx.doi.org/10.1016/j.gene.2017.07.082, doi:10.1016/j.gene.2017.07.082. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2017.07.082)

[6. (Huang2021Mdfi) Bo Huang, Yiren Jiao, Yifan Zhu, Zuocheng Ning, Zijian Ye, Qing X. Li, Chingyuan Hu, and Chong Wang. Mdfi promotes c2c12 cell differentiation and positively modulates fast-to-slow-twitch muscle fiber transformation. Frontiers in Cell and Developmental Biology, January 2021. URL: http://dx.doi.org/10.3389/fcell.2021.605875, doi:10.3389/fcell.2021.605875. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.605875)